



NASDAQ: ATNF

Leading Research into Solving One of the World's
Largest Drivers of Disease: **INFLAMMATION**

Corporate Presentation
April 2023



Disclaimer

This Presentation is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, debt or other financial instruments of 180 LIFE SCIENCES Corp. ("180 Life Sciences" or the "Company") or any of its affiliates. This Presentation has been prepared to assist interested parties in making their own evaluation with respect to the business of 180 LIFE SCIENCES and for no other purpose. The information contained herein does not purport to be all-inclusive. The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any projections or any other information contained herein. Any data on past performance or projections contained herein is no indication as to future performance. 180 LIFE SCIENCES assumes no obligation to update the information in this Presentation.

Forward-Looking Statements

This Presentation includes "forward-looking statements" within the meaning of U.S. securities laws. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation, statements relating to the company's continued listing on the Nasdaq Stock Market; expectations regarding the future capitalization, resources and ownership structure of the company; the inability to recognize the anticipated benefits of the business, which may be affected by, among other things, the ability of the company to execute its plans to develop and market new drug products and the timing, costs and results of these development programs; estimates of the size of the markets for the company's potential drug products; potential litigation involving the company; the validity or enforceability of the company's intellectual property, including any challenges thereto; global economic conditions; geopolitical events and regulatory changes; access to additional financing; the duration and ongoing impact of the COVID-19 pandemic; and other risks and uncertainties indicated from time to time in the company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. Additional information concerning these and other risk factors is contained in the company's most recent filings with the SEC. All subsequent written and oral forward-looking statements concerning the company and attributable to the company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The company does not undertake any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

180 Life Sciences Overview



Robust IP-Protected Product Pipeline with Large Market Potential

- **Three families of drugs** address significant market opportunities in inflammation, fibrosis and pain with multiple programs in synchronized stages of development
 - **Fibrosis & Anti-TNF**
 - **Synthetic CBD Analogs (SCAs)**
 - **α7nAChR**
- **Strong IP Portfolio:** 24 granted patents, 33 filed patent applications



Numerous Near-Term Inflection Points

- **Anti-TNF programs:** expecting to initiate a Phase 2 trial in Q2/Q3 2023 in POCD with initial data expected in Q2 2025
- **SCA programs:** validation ongoing, with a planned toxicity study






Scientific Pioneers Backed by Experienced Operators and Board

- **Founders:** pioneers with 100+ cumulative years of discovery and clinical experience; successes include Remicade and Tysabri
- **Board:** seasoned and diverse executives with broad skillsets that complement the Company's needs
- **Senior Management:** operators with decades of experience at large & small life sciences companies



Leading Research
into Solving One of
the World's Largest
Drivers of Disease:
INFLAMMATION

Three Therapeutic Families Targeting Multiple Indications

	Indication	Early-Stage Development		Late-Stage Development		Milestones
		Discovery/Validation	Phase 1	Phase 2	Phase 3	
 Fibrosis & Anti-TNF*	Dupuytren's Contracture	adalimumab				Pursuing Conditional Marketing Authorization in UK
	Frozen Shoulder	adalimumab				UK feasibility study closed, new clinical trial site and country to be determined
	POCD	infliximab				Initiate Phase 2 Q2/Q3 2023
	NASH					Ongoing Validation
	HMGB1					Ongoing Validation
 Synthetic CBD Analogs (SCAs)	Chronic Pain					Ongoing Validation
	Early Arthritis					Ongoing Validation
 Nicotine Acetylcholine Receptor (α7nAChR)	Smoking Cessation Induced Ulcerative Colitis					Ongoing Validation

*Repurposed drugs in new indications may not need to follow standard regulatory approval pathways. Regulatory approvals obtained from the MHRA and CCMO and the relevant accredited ethics committees to perform clinical trials in the UK and The Netherlands. No marketing applications or requests for marketing approval have been submitted to the FDA for any products at this time.



Experienced Leadership Team

Management Team



James Woody, MD, PhD
Director, CEO



Jonathan Rothbard, PhD
Chief Scientific Officer



Ozan Pamir
Chief Financial Officer

Founders



Prof. Sir Marc Feldmann
*Executive Co-Chairman
Co-Founder
University of Oxford*



Prof. Lawrence Steinman
*Executive Co-Chairman
Co-Founder
Stanford University*



Prof. Raphael Mechoulam
*Co-Founder
Hebrew University*



Prof. Jagdeep Nanchahal
*Co-Founder; Chair,
Clinical Advisory Board
University of Oxford*

Board of Directors

Prof. Sir Marc Feldmann
Co-Chairman

Prof. Lawrence Steinman
Co-Chairman

James Woody, MD, PhD
Chief Executive Officer

Teresa DeLuca, MD, MBA
Independent Director

Frank Knuettel II, MBA
Independent Director

Pamela Marrone, PhD
Independent Director

Prof. Larry Gold, PhD
Independent Director

Donald McGovern, Jr.
Independent Director

Russell Ray, MBA
Independent Director

